Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-1207 for Benign Prostatic Hyperplasia
NCT00945490Phase 3Completed
- Sponsor
- Nymox Pharmaceutical
- Start
- May 2009
- Primary completion
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of fexapotide triflutate in benign prostatic hyperplasia (BPH), sponsored by Nymox Pharmaceutical. Started May 2009; status: completed.
02
Drugs
fexapotide triflutate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00945490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00945490.